Regulated information

Get easy access to all the information you need. The documentation center allows you to open, send by e-mail or download any document. Feel free to use the filters and add several documents to your basket.
121 result(s)
27/07/2017
18:02
719.45 KB

At its meeting on July 26, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the financial statements for the first half of 2017.

27/07/2017
18:00
424.65 KB

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2017 

26/04/2017
14:24
670.25 KB

The registration document of Vetoquinol relative to fiscal year 2016, including the annual financial report relative to fiscal year 2016, was filed with the Autorité des marchés financiers ("the AMF") on April 26, 2017.

13/04/2017
17:41
424.57 KB

Consolidated sales for Q1 2017 amounted to €86.1 million, up 0.4% as reported from the same period last year. Sales were boosted by a 1.8% positive currency impact mainly related to non-European currencies. Q1 sales fell 1.4% like-for-like. 

22/03/2017
17:45
439.91 KB

At its meeting on March 22, 2017, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2016 financial statements. 

26/01/2017
18:00
424.59 KB

The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%.

12/12/2016
18:00
167.27 KB
December 12, 2016 (Lure, France) – Vetoquinol published its calendar of financial communication for 2017.
18/10/2016
17:19
419.37 KB

Vetoquinol posted sales of €257.5 million for the first nine months of 2016, up 2.3% compared to the same period last year. Organic growth for the period came to 4.8%, curbed by a 2.5% negative currency impact. 

29/09/2016
16:29
227.37 KB

The veterinary pharmaceutical company Vetoquinol launches its employer brand. For 83 years, Vetoquinol has been building its future, drawing on relationships of trust with its partners, the development of every employee, and its long-held belief of continuous improvement. Following on from its corporate brand, the company is now positioning itself as a high-quality employer.

28/07/2016
18:15
407.32 KB

Communiqué de mise à disposition  du rapport financier semestriel relatif à l’exercice 2016 

28/07/2016
18:00
429.17 KB

Sales growth across all territories : reference products up 5.0

27/04/2016
11:34
408.88 KB

The Registration document of Vetoquinol relative to fiscal year 2015, including the Annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 26, 2016.

19/04/2016
19:28
413.62 KB

 

Vetoquinol posted Q1 2016 sales of €85.8 million, representing organic growth of 7.7%. Changes in exchange rates resulted in a negative currency impact of 2.1%; reported sales for the first three months of 2016 grew by 5.6%.

21/03/2016
18:00
919.37 KB

At its meeting on March 18, 2016, the Vetoquinol S.A. Board of Directors reviewed the Group’s results and approved the 2015 financial statements.

08/02/2016
15:11
418.94 KB
The Vetoquinol Group posted 2015 sales of €342.6 million, up 8.7% on reported data and up 3.8% at constant exchange rates. The Group benefited from a positive currency impact of 4.9% mainly linked to the US dollar, Indian rupee and British pound.
03/12/2015
01:00
574.16 KB
Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan.
22/10/2015
19:45
420.05 KB
Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%.
14/09/2015
19:45
409.87 KB
Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs.
30/07/2015
20:00
549.27 KB
The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements.
Basket
Empty basket

INVESTORS CORNER

Vetoquinol has been listed on the Euronext Paris stock market since November 16th.

Consult the documents of the Meeting

Contact

Composition of the bodies of Corporate Management and Governance

Financial information and key figures: annual, half-year and by sector key figures